J&J Ramps Up Manufacturing Capacity To Produce 1 Billion Doses Of Candidate COVID-19 Vaccine
Executive Summary
Company expects clinical trials to begin by September and says first batches could be available for emergency use authorization in early 2021; J&J pledges vaccine will be available to public on not-for-profit basis.
You may also be interested in...
Multiple Coronavirus Vaccines Is Policy Aim, But Will Complicate Supply Chain
At Senate hearing, FDA and NIH officials say government and vaccine developers are outlining production needs with ability to shift manufacturing from their candidates to others to ensure production of the most promising products. FDA Commissioner Hahn says as an essential worker he would break quarantine if needed at a critical White House or other meeting.
Trump’s Rhetorical Pivot On Pharma: The Hucksterism Is Still A Threat
It is nice for pharma CEOs to be called ‘brilliant’ by a President who once said they are ‘getting away with murder.’ But the ‘new’ Trump rhetoric still has major pitfalls for industry – including a fundamental risk of undermining regulatory standards.
J&J Q1 Financials Are All About COVID-19 Progress And Impact
Johnson & Johnson will move a vaccine candidate for COVID-19 into clinical testing in September and lowered 2020 financial guidance as a result of the pandemic. Pharma sales were resilient, however.